'The increase in Cash is primarily attributable to $55,000,
of revenue received in cash pursuant to a license granted by the Company to Oncology Pharma, Inc. and $300,000 received by the Company from the sale of investment securities offset by expenses paid in the operation of the Company’s business, a loan made to an entity under common control, and the paying down of $47,900 of principal indebtedness owed by the Company to an entity under common control.'